美国 · SEC FORM 4
Day One Biopharmaceuticals, Inc.
DAWN · — · CIK 0001845337 · Healthcare
内部人信号
当前没有活跃买入信号
0 qualifying P purchase groups
当前 180 天评分窗口
14 同一窗口内观察到的 Form 4 交易行
0 sales · 14 期权、代扣税、授予、赠与或其他交易行
最近一次合资格买入2023-10-20 · ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len · $1.1M
为什么没有活跃信号？
买入活动无
近期买入无
近期卖出无
买入信号状态未激活
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
Cluster未计算
买入规模未计算
角色未计算
近期性未计算
确信度未计算
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型；卖出仅作为背景。
AprMayJunJulAugSepOct
ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik LenTenPercentOwner
○
VASCONCELLES MICHAELHead of Research and Dev.
○
Bender JeremyCHIEF EXECUTIVE OFFICER
○
York Charles N IICOO and CFO
○
Dubow AdamGen Counsel & Secretary
○
Holles Natalie C.Director
○
● 买入▼ 卖出○ 其他
Showing the six most active owners; 3 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
暂无已记录的活跃信号快照
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2023-10-20 · ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len.
近期 Form 4 活动
0买入
9卖出
44其他 Form 4 交易行
19SEC 申报 · 365天
买入0 qualifying P line(s) · 180 days
卖出0 sale line(s) · 仅供背景
其他14 exercise / withholding / award / gift / other lines
10b5-1／计划交易Not assessed
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
FINRA 报告中没有该股票代码的空头余额。
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2023-10-20 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 111,387 | USD 9.97 | USD 1,110,528 | SEC 申报 ↗ |
| 2023-10-19 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 384,400 | USD 10.06 | USD 3,867,064 | SEC 申报 ↗ |
| 2023-10-18 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 979,667 | USD 10.21 | USD 10,002,400 | SEC 申报 ↗ |
| 2023-06-09 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 769,230 | USD 13.00 | USD 9,999,990 | SEC 申报 ↗ |
| 2022-06-17 | Gladstone Michael | 买入 (P) | Common Stock | 766,667 | USD 15.00 | USD 11,500,005 | SEC 申报 ↗ |
| 2022-06-17 | Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P.; Atlas Venture Opportunity Fund II, L.P. | 买入 (P) | Common Stock | 766,667 | USD 15.00 | USD 11,500,005 | SEC 申报 ↗ |
| 2022-06-17 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 1,200,000 | USD 15.00 | USD 18,000,000 | SEC 申报 ↗ |
| 2022-01-20 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 4,615 | USD 14.73 | USD 67,979 | SEC 申报 ↗ |
| 2022-01-19 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 58,818 | USD 14.70 | USD 864,625 | SEC 申报 ↗ |
| 2022-01-18 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 43,429 | USD 14.26 | USD 619,298 | SEC 申报 ↗ |
| 2021-06-01 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day 1 LLC; Access Industries Holdings LLC; Blavatnik Len | 买入 (P) | Common Stock | 875,000 | USD 16.00 | USD 14,000,000 | SEC 申报 ↗ |
| 2021-06-01 | Grant Papanek Julie | 买入 (P) | Common Stock | 13,000 | USD 16.00 | USD 208,000 | SEC 申报 ↗ |
| 2021-06-01 | Canaan Partners XI LLC; Canaan XI L.P. | 买入 (P) | Common Stock | 13,000 | USD 16.00 | USD 208,000 | SEC 申报 ↗ |
| 2021-06-01 | Atlas Venture Associates Opportunity I, L.P.; Atlas Venture Associates Opportunity I, LLC; Atlas Venture Associates XI, L.P.; Atlas Venture Associates XI, LLC; Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P. | 买入 (P) | Common Stock | 250,000 | USD 16.00 | USD 4,000,000 | SEC 申报 ↗ |
| 2021-06-01 | Josey John A. | 买入 (P) | Common Stock | 7,000 | USD 16.00 | USD 112,000 | SEC 申报 ↗ |
Form 4 申报证据
53 transaction lines in the latest 365-day window; 384 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-23 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | U (U) | Common Stock | 12,929,322 | USD 21.50 | USD 277,980,423 | SEC 申报 ↗ |
| 2026-04-23 | York Charles N II | D (D) | Common Stock | 312,025 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | VASCONCELLES MICHAEL | D (D) | Common Stock | 4,397 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (28 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-04-23 | ACCESS INDUSTRIES MANAGEMENT, LLC; AI Day1 LLC; Access Industries Holdings LLC; Blavatnik Len | U (U) | Common Stock | 12,929,322 | USD 21.50 | USD 277,980,423 | SEC 申报 ↗ |
| 2026-04-23 | York Charles N II | D (D) | Common Stock | 312,025 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | VASCONCELLES MICHAEL | D (D) | Common Stock | 4,397 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Ramasastry Saira | D (D) | Common Stock | 40,485 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Merendino Lauren | D (D) | Common Stock | 60,157 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Josey John A. | D (D) | Common Stock | 72,292 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Holles Natalie C. | D (D) | Common Stock | 57,310 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Dubow Adam | D (D) | Common Stock | 72,694 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-23 | Bender Jeremy | D (D) | Common Stock | 1,499,031 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-17 | York Charles N II | 卖出 (S) | Common Stock | 6,065 | USD 11.60 | USD 70,354 | SEC 申报 ↗ |
| 2026-02-17 | VASCONCELLES MICHAEL | 卖出 (S) | Common Stock | 2,728 | USD 11.60 | USD 31,645 | SEC 申报 ↗ |
| 2026-02-17 | Merendino Lauren | 卖出 (S) | Common Stock | 5,814 | USD 11.60 | USD 67,442 | SEC 申报 ↗ |
| 2026-02-17 | Dubow Adam | 卖出 (S) | Common Stock | 6,395 | USD 11.60 | USD 74,182 | SEC 申报 ↗ |
| 2026-02-17 | Bender Jeremy | 卖出 (S) | Common Stock | 15,459 | USD 11.60 | USD 179,324 | SEC 申报 ↗ |
| 2026-02-15 | York Charles N II | 期权行权／转换 (M) | Common Stock | 16,750 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-15 | VASCONCELLES MICHAEL | 期权行权／转换 (M) | Common Stock | 7,125 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-15 | Merendino Lauren | 期权行权／转换 (M) | Common Stock | 15,162 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-15 | Dubow Adam | 期权行权／转换 (M) | Common Stock | 16,463 | USD — | USD — | SEC 申报 ↗ |
| 2026-02-15 | Bender Jeremy | 期权行权／转换 (M) | Common Stock | 42,937 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-25 | Bender Jeremy | 赠与 (G) | Common Stock | 307,225 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2025-11-17 | York Charles N II | 卖出 (S) | Common Stock | 4,062 | USD 8.91 | USD 36,192 | SEC 申报 ↗ |
| 2025-11-17 | Merendino Lauren | 卖出 (S) | Common Stock | 3,726 | USD 8.91 | USD 33,199 | SEC 申报 ↗ |
| 2025-11-17 | Dubow Adam | 卖出 (S) | Common Stock | 4,319 | USD 8.91 | USD 38,482 | SEC 申报 ↗ |
| 2025-11-17 | Bender Jeremy | 卖出 (S) | Common Stock | 15,894 | USD 8.91 | USD 141,616 | SEC 申报 ↗ |
| 2025-11-15 | York Charles N II | 期权行权／转换 (M) | Common Stock | 10,250 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-15 | Merendino Lauren | 期权行权／转换 (M) | Common Stock | 6,849 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-15 | Dubow Adam | 期权行权／转换 (M) | Common Stock | 8,400 | USD — | USD — | SEC 申报 ↗ |
| 2025-11-15 | Bender Jeremy | 期权行权／转换 (M) | Common Stock | 20,007 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | DAWN |
| CIK | 0001845337 |
| 行业 | Healthcare |
| 细分行业 | — Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | — |
数据覆盖
| 本地 Form 4 历史 | 384 transaction lines from 2021-06-01 to 2026-04-23 16 P purchase lines · 181 S sale lines · 187 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.